FDA-Drug2026-08-19Class IIPROCESSING DEFECT

Shoolin Pharma Chem sildenafil citrate recalled for CGMP manufacturing deviations

OTHERNationwide distributionDrugs

What this means

The FDA identified Current Good Manufacturing Practice (CGMP) deviations during an inspection of Shoolin Pharma Chem LLP's facility in India. Sildenafil citrate bulk powder (batch SDC2505001, expiring April 30, 2030) distributed nationwide for prescription compounding did not meet required manufacturing standards.

  • If you are a pharmacy or compounding facility, do not use sildenafil citrate from batch SDC2505001.
  • Contact your supplier or the FDA for guidance on affected inventory.
  • Consult the FDA's full recall notice for specific lot numbers and distribution details.
Get recalls like this in a free plain-English brief every Sunday.Get alerts ↓
The agency's original wording
Hazard

CGMP Deviations:Noted during FDA inspection

Intended for
Adults
Illnesses reported
None reported
Sold states
Distributed Nationwide in the USA
Affected count
25KG, 250-1gm bags
Manufactured in
408 B/H Ratnamani Tubes, Block/Survey No; Nr Maruti Inox, Kadi, India
Products
SILDENAFIL CITRATE USP, 0.100 KG, 100 gm-bag Net Wt, RX ONLY "FOR Prescription Compounding Only", Shoolin Pharma Chem LLP, Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesana, Gujarat, 382715, India, (CAS NO. 171599-83-0) NDC 85702-001-05

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0759-2026

More Shoolin Pharma Chem recalls

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Free · One email a week · Unsubscribe anytime
By signing up you agree to our Terms and Privacy Policy.